<- Go Home
Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. was formerly a subsidiary of Indivior PLC.
Market Cap
$108.8M
Volume
58.3K
Cash and Equivalents
$35.4M
EBITDA
-$31.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$7.1M
Profit Margin
31.85%
52 Week High
$29.25
52 Week Low
$7.34
Dividend
N/A
Price / Book Value
5.20
Price / Earnings
-3.12
Price / Tangible Book Value
5.20
Enterprise Value
$89.9M
Enterprise Value / EBITDA
-2.96
Operating Income
-$31.5M
Return on Equity
105.87%
Return on Assets
-35.51
Cash and Short Term Investments
$35.4M
Debt
$16.5M
Equity
$20.5M
Revenue
$22.3M
Unlevered FCF
-$2.0M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium